

# Initial Tumor Metabolic Parameters (Maximum SUV and Metabolic Volume) Predict Death From Lung Cancer and Rapid SUV Decline is Associated with Local Control

Maria Werner-Wasik, Edward Pequignot, Terry Hyslop, Brian Shull<sup>#</sup>, Ying Xiao, Mitchell Machtay, Amy Taylor, Walter Curran\* and Rita Axelrod

Jefferson Medical College of Thomas Jefferson University and <sup>#</sup>Jefferson Center City Imaging, Philadelphia, PA., \*Emory University, Atlanta, GA

## Rationale and Objectives

- Factors associated with local failure and death from lung cancer were evaluated based on post-treatment FDG-PET imaging in patients (pts) with non-small cell lung cancer (NSCLC).
- PET-CT scans were obtained 6-8 weeks after thoracic RT and approximately every 3 months thereafter.

## Materials and Methods

- Patient Population:** 50 pts with NSCLC who received thoracic RT (with or without chemotherapy) between 2004-2008 were eligible if they had pre-RT PET scan and at least one post-RT PET scan.
- Methods:** Primary tumor and hypermetabolic lymph nodes included in the RT field were contoured on the initial and post-treatment PET scans applying a gradient "PET edge" technique (Mimvista Corp, Cleveland, OH). PET edge is superior to the percent threshold techniques (i.e. 25%, 30% max SUV etc) (Nelson A et al, ASTRO 2009 abstract #2993) with regard to reflecting true tumor volume.
- Maximum SUV (MaxSUV) and the Metabolic Tumor Volume (MTV) of the primary tumor and involved lymph nodes were measured using the same software.
- Statistics:** MTV and Max SUV were assessed longitudinally, providing for each patient separate log transformed initial estimates and changes (value at time 0 - value at time 1). Competing risks analysis of time to local failure and death were completed using the methods of Gray (Gray RJ, J Ann Stat 1988; 16:1141-1154.), as implemented in the R package CMPSK. Results are reported as hazard ratios, 95% confidence interval of hazard ratio, and 2-sided p-values.

## Results: Patient Characteristics


Characteristic	Number (range)
Gender F:M	33 : 17
Median age	63
Stage: I	5
III	29
IV	11
recurrent	5
Median RT dose	60 (range 35-71)
BED dose	73.2
Number of pts with <u>post-RT</u> PET scans	50 (1 PET scan) 26 (2 scans) 11 (3 scans) 4 (4 scans) 4 (5 scans) 3 (6 scans)

## Results

- A total of 262 primary tumors and/or lymph nodes were analyzed.
- Median FU time: 14.2 mo (range 2-52.2)
- Metabolic complete response (mCR, SUV<sub>2.5</sub>) was achieved in 38% patients. LF occurred in 10 pts.
- The primary tumor median MaxSUV declined by 72% by the 1<sup>st</sup> post-RT PET, 76% by the 2<sup>nd</sup> and 77% by the 3<sup>rd</sup>.
- Median time to local failure (LF) not reached (75th %: 24 mo); MST 31 mo.


## Results: Metabolic Response After RT

Metric	Pre-RT	Post-RT #1	Post-RT #2
<b>Tumor Max SUV</b>	<b>12.3</b> (1.9-31)	3.4 (0.9-20.9)	2.9 (1-22.5)
<b>Lymph nodes Max SUV</b>	9.1 (2-23.7)	2.8 (1.5-7.9)	2.8 (1.5-8.9)
<b>MTV (tumor + lymph nodes)</b>	51.1 cc (1.5-491)	37.3 cc (3-585)	22.9 cc (2-153)




**Fig.1. Local failure in Patients with Stages I-III**

Local failure was defined as increase in MaxSUV of either the primary tumor or lymph nodes in the RT field, with any accompanying increase in size of the tumor on a CT scan.



**Fig.2. Local failure in Patients with Stage IV**



### Legend to Figures 1 and 2:

- Blue = hi change in MTV, low change in SUV
- Red = low change in MTV, low change in SUV
- Turquoise = high change in MTV, high change in SUV
- Green = low change in MTV, high change in SUV

## Variables Associated with Local Failure: Multivariate Analysis

Variable	HR	p-value
Age	0.98	0.46
Sex (F/M)	0.81	0.76
Stage	15.35	0.009
BED RT total dose Lo/Hi1	2.15	0.31
Pre-treatment MTV	3.45	0.19
Change in MTV (continuous)	10.45	0.057
Pre-treatment SUV	5.9	0.44
Change in SUV	0.082	0.045

## Variables Associated with Death: Multivariate Analysis

Variable	HR	p-value
Age	1.035	0.17
Sex (F/M)	6.21	0.11
Stage	1.44	0.79
BED RT total dose Lo/Hi	0.29	0.31
Pre-treatment MTV (categor.)	6.36	0.016
Change in MTV	0.24	0.11
Pre-treatment SUV (contin.)	1.05	0.037
Change in SUV	0.54	0.79

## Conclusions

- LF after thoracic RT is not common (20%) during lifetime of pts receiving 3D thoracic RT and the rate of metabolic response is rapid.
- Higher pre-treatment maximum SUV and MTV > 51 cc are associated with increased risk of death from lung cancer.
- Rapid post-treatment decline in SUV on first follow-up PET scan is associated with subsequent lower risk of local failure.
- However, the decline in MTV was paradoxically associated with eventual increased failure. We hypothesize this may be related to the aggressive tumors which respond quickly yet recur faster.
- Patients with Stage IV lung cancer are more likely to experience local failure than lower stage patients, which may be due to the lower thoracic RT doses.